The role of TNF- α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Galeone, Antonella ^a   Paparella, Domenico ^a   Colucci, Silvia ^a   Grano, Maria ^a   Brunetti, Giacomina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AORTA STENOSIS; AORTA VALVE DISEASE; APOPTOSIS; BONE MASS; CALCIFIC AORTIC VALVE DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; OSTEOCLASTOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; AORTA VALVE; ARTICLE; CALCINOSIS; CONGENITAL HEART MALFORMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VALVULAR HEART DISEASE;

AORTIC VALVE; CALCINOSIS; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888625752     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/875363     Document Type: Review

References (137)

1. Freeman R. V., Otto C. M., Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005 111 24 3316 3326 2-s2.0-21044437380 10.1161/CIRCULATIONAHA.104.486738 (Pubitemid 40875006)
2. Iung B., Baron G., Butchart E. G., Delahaye F., Gohlke-Bärwolf C., Levang O. W., Tornos P., Vanoverschelde J., Vermeer F., Boersma E., Ravaud P., Vahanian A., A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. European Heart Journal 2003 24 13 1231 1243 2-s2.0-0038267070 10.1016/S0195-668X(03)00201-X (Pubitemid 36834640)
3. Nkomo V. T., Gardin J. M., Skelton T. N., Gottdiener J. S., Scott C. G., Enriquez-Sarano M., Burden of valvular heart diseases: a population-based study. The Lancet 2006 368 9540 1005 1011 2-s2.0-33748453667 10.1016/S0140-6736(06) 69208-8 (Pubitemid 44353666)
4. Stewart B. F., Siscovick D., Lind B. K., Gardin J. M., Gottdiener J. S., Smith V. E., Kitzman D. W., Otto C. M., Clinical factors associated with calcific aortic valve disease. Journal of the American College of Cardiology 1997 29 3 630 634 2-s2.0-0031051128 10.1016/S0735-1097(96)00563-3 (Pubitemid 27116107)
5. Lindroos M., Kupari M., Heikkila J., Tilvis R., Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. Journal of the American College of Cardiology 1993 21 5 1220 1225 2-s2.0-0027477079 (Pubitemid 23106200)
6. Rajamannan N. M., Evans F. J., Aikawa E., Grande-Allen K. J., Demer L. L., Heistad D. D., Simmons C. A., Masters K. S., Mathieu P., O'Brien K. D., Schoen F. J., Towler D. A., Yoganathan A. P., Otto C. M., Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Circulation 2011 124 16 1783 1791 2-s2.0-80054937214 10.1161/ CIRCULATIONAHA.110.006767
7. Jian B., Narula N., Li Q., Mohler E. R. III, Levy R. J., Progression of aortic valve stenosis: TGF- β 1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Annals of Thoracic Surgery 2003 75 2 457 465 2-s2.0-0037314647 10.1016/S0003-4975(02) 04312-6 (Pubitemid 36184488)
8. Galeone A., Brunetti G., Oranger A., Greco G., Di Benedetto A., Mori G., Colucci S., Zallone A., Paparella D., Grano M., Aortic valvular interstitial cells apoptosis and calcification is mediated by TNF-related apoptosis-inducing ligand. International Journal of Cardiology 2013 10.1016/j.ijcard.2013.09.012
9. Olsson M., Dalsgaard C., Haegerstrand A., Rosenqvist M., Rydén L., Nilsson J., Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. Journal of the American College of Cardiology 1994 23 5 1162 1170 2-s2.0-0028329052 (Pubitemid 24117151)
10. Otto C. M., Kuusisto J., Reichenbach D. D., Gown A. M., O'Brien K. D., Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994 90 2 844 853 2-s2.0-0027991976 (Pubitemid 24242754)
11. O'Brien K. D., Reichenbach D. D., Marcovina S. M., Kuusisto J., Alpers C. E., Otto C. M., Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 4 523 532 2-s2.0-0029872345 (Pubitemid 26107723)
12. Olsson M., Thyberg J., Nilsson J., Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 5 1218 1222 2-s2.0-0032936072 (Pubitemid 29227640)
13. Muller A. M., Cronen C., Kupferwasser L. I., Oelert H., Muller K. M., Kirkpatrick C. J., Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. Journal of Pathology 2000 191 1 54 60 10.1002/(SICI)1096-9896(200005)191:1<54::AID- PATH568>3.0.CO;2-Y (Pubitemid 30235649)
14. Kaden J. J., Dempfle C., Grobholz R., Tran H., Kiliç R., Sarikoç A., Brueckmann M., Vahl C., Hagl S., Haase K. K., Borggrefe M., Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003 170 2 205 211 2-s2.0-10744223993 10.1016/S0021-9150(03)00284-3 (Pubitemid 37377791)
15. Kaden J. J., Kiliç R., Sarikoç A., Hagl S., Lang S., Hoffmann U., Brueckmann M., Borggrefe M., Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. International Journal of Molecular Medicine 2005 16 5 869 872 2-s2.0-33644619491
16. Edep M. E., Shirani J., Wolf P., Brown D. L., Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovascular Pathology 2000 9 5 281 286 2-s2.0-0033735304 10.1016/S1054-8807(00)00043-0
17. Mohler E. R. III, Gannon F., Reynolds C., Zimmerman R., Keane M. G., Kaplan F. S., Bone formation and inflammation in cardiac valves. Circulation 2001 103 11 1522 1528 2-s2.0-0035916929 (Pubitemid 32226259)
18. Boström K., Watson K. E., Stanford W. P., Demer L. L., Atherosclerotic calcification: relation to developmental osteogenesis. The American Journal of Cardiology 1995 75 6 88B 91B 2-s2.0-0028906991
19. Demer L. L., A skeleton in the atherosclerosis closet. Circulation 1995 92 8 2029 2032 2-s2.0-0028860525
20. Mohler E. R. III, Chawla M. K., Chang A. W., Vyavahare N., Levy R. J., Graham L., Gannon F. H., Identification and characterization of calcifying valve cells from human and canine aortic valves. Journal of Heart Valve Disease 1999 8 3 254 260 2-s2.0-0033057678 (Pubitemid 29274326)
21. Mohler E. R., Adam L. P., McClelland P., Graham L., Hathaway D. R., Detection of osteopontin in calcified human aortic valves. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 3 547 552 2-s2.0-0030944507 (Pubitemid 27133146)
22. O'Brien K. D., Kuusisto J., Reichenbach D. D., Ferguson M., Giachelli C., Alpers C. E., Otto C. M., Osteopontin is expressed in human aortic valvular lesions. Circulation 1995 92 8 2163 2168 2-s2.0-0028823030
23. Aggarwal B. B., Gupta S. C., Kim J. H., Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012 119 3 651 665 2-s2.0-84856074741 10.1182/blood-2011-04-325225
24. Kriegler M., Perez C., DeFay K., Albert I., Lu S. D., A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988 53 1 45 53 2-s2.0-0024281428
25. Tang P., Hung M. C., Klostergaard J., Human pro-tumor necrosis factor is a homotrimer. Biochemistry 1996 35 25 8216 8225 2-s2.0-0030055168 10.1021/bi952182t (Pubitemid 26234923)
26. Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K. A., Gerhart M., Davis R., Fitzner J. N., Johnson R. S., Paxton R. J., March C. J., Cerretti D. P., A metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. Nature 1997 385 6618 729 733 2-s2.0-8044257704 10.1038/385729a0 (Pubitemid 27098094)
27. Pfeffer K., Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine and Growth Factor Reviews 2003 14 3-4 185 191 2-s2.0-0037644804 10.1016/S1359-6101(03)00022-4 (Pubitemid 36693140)
28. Popa C., Netea M. G., van Riel P. L. C. M., van der Meer J. W. M., Stalenhoef A. F. H., The role of TNF- α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research 2007 48 4 751 762 2-s2.0-34147126829 10.1194/jlr.R600021-JLR200 (Pubitemid 46557880)
29. Hsu H., Xiong J., Goeddel D. V., The TNF receptor 1-associated protein TRADD signals cell death and NF- B activation. Cell 1995 81 4 495 504 2-s2.0-0029007855
30. Hsu H., Shu H. B., Pan M. G., Goeddel D. V., TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996 84 2 299 308 2-s2.0-0030032106 10.1016/S0092-8674(00)80984-8 (Pubitemid 26042835)
31. Morgan M. J., Liu Z. G., Reactive oxygen species in TNF α -induced signaling and cell death. Molecules and Cells 2010 30 1 1 12 2-s2.0-77955035878 10.1007/s10059-010-0105-0
32. Aggarwal B. B., Nuclear factor- B: the enemy within. Cancer Cell 2004 6 3 203 208 2-s2.0-4544342570 10.1016/j.ccr.2004.09.003 (Pubitemid 39222032)
33. Takeuchi M., Rothe M., Goeddel D. V., Anatomy of TRAF2: distinct domains for nuclear factor- B activation and association with tumor necrosis factor signaling proteins. The Journal of Biological Chemistry 1996 271 33 19935 19942 2-s2.0-0029786304 10.1074/jbc.271.33.19935 (Pubitemid 26281739)
34. Chen Z. J., Ubiquitin signalling in the NF- B pathway. Nature Cell Biology 2005 7 8 758 765 2-s2.0-23144449789 10.1038/ncb0805-758 (Pubitemid 41079044)
35. Hayden M. S., Ghosh S., Signaling to NF- B. Genes and Development 2004 18 18 2195 2224 2-s2.0-4444376712 10.1101/gad.1228704 (Pubitemid 39209568)
36. Vallabhapurapu S., Karin M., Regulation and function of NF- B transcription factors in the immune system. Annual Review of Immunology 2009 27 693 733 2-s2.0-67650724069 10.1146/annurev.immunol.021908.132641
37. Aggarwal B. B., Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003 3 9 745 756 2-s2.0-0141465062 10.1038/nril184 (Pubitemid 41070815)
38. Natoli G., Costanzo A., Moretti F., Fulco M., Balsano C., Levrero M., Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor B (NF B)-inducing kinase requirement for activation of activating protein 1 and NF B but not of c-Jun N-terminal kinase/stress-activated protein kinase. The Journal of Biological Chemistry 1997 272 42 26079 26082 2-s2.0-0030666194 10.1074/jbc.272.42.26079 (Pubitemid 27458811)
39. Brietzke E., Kapczinski F., TNF- α as a molecular target in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 6 1355 1361 2-s2.0-47749101679 10.1016/j.pnpbp.2008.01.006 (Pubitemid 352033661)
40. Matera M. G., Calzetta L., Cazzola M., TNF- α inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulmonary Pharmacology and Therapeutics 2010 23 2 121 128 2-s2.0-75749095929 10.1016/j.pupt.2009.10.007
41. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
42. Roato I., Grano M., Brunetti G., Colucci S., Mussa A., Bertetto O., Ferracini R., Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal 2005 19 2 228 230 2-s2.0-13244273716 10.1096/fj.04-1823fje (Pubitemid 40189264)
43. D'Amelo P., Grimaldi A., Pescarmona G. P., Tamone C., Roato I., Isaia G., Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB Journal 2005 19 3 410 412 2-s2.0-14644439140 10.1096/fj.04-2214fje (Pubitemid 40316533)
44. Brunetti G., Colucci S., Pignataro P., Coricciati M., Mori G., Cirulli N., Zallone A., Grassi F. R., Grano M., T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. Journal of Periodontology 2005 76 10 1675 1680 2-s2.0-27844548531 10.1902/jop.2005.76.10. 1675 (Pubitemid 41645576)
45. Colucci S., Brunetti G., Cantatore F. P., Oranger A., Mori G., Quarta L., Cirulli N., Mancini L., Corrado A., Grassi F. R., Grano M., Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNF α and IL-7 in an in vitro model derived from human psoriatic arthritis. Journal of Pathology 2007 212 1 47 55 2-s2.0-34248582794 10.1002/path.2153 (Pubitemid 46746289)
46. Feldman A. M., Combes A., Wagner D., Kadakomi T., Kubota T., You Li Y., McTiernan C., The role of tumor necrosis factor in the pathophysiology of heart failure. Journal of the American College of Cardiology 2000 35 3 537 544 2-s2.0-0034162801 10.1016/S0735-1097(99)00600-2 (Pubitemid 30167009)
47. McKellar G. E., McCarey D. W., Sattar N., McInnes I. B., Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews Cardiology 2009 6 6 410 417 2-s2.0-69249222895 10.1038/nrcardio.2009.57
48. Tintut Y., Patel J., Parhami F., Demer L. L., Tumor necrosis factor- α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000 102 21 2636 2642 2-s2.0-0034700234
49. Kaden J. J., Dempfle C., Grobholz R., Fischer C. S., Vocke D. C., Kiliç R., Sarikoç A., Piñol R., Hagl S., Lang S., Brueckmann M., Borggrefe M., Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovascular Pathology 2005 14 2 80 87 2-s2.0-20144377112 10.1016/j.carpath.2005.01.002 (Pubitemid 40381303)
50. Yu Z., Seya K., Daitoku K., Motomura S., Fukuda I., Furukawa K., Tumor necrosis factor- α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. Journal of Pharmacology and Experimental Therapeutics 2011 337 1 16 23 2-s2.0-79953012725 10.1124/jpet.110.177915
51. Mohty D., Pibarot P., Després J., Côté C., Arsenault B., Cartier A., Cosnay P., Couture C., Mathieu P., Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1 187 193 2-s2.0-37549064021 10.1161/ATVBAHA.107.154989
52. Isoda K., Matsuki T., Kondo H., Iwakura Y., Ohsuzu F., Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 4 708 715 2-s2.0-77950889002 10.1161/ATVBAHA.109.201749
53. Kapadia S. R., Yakoob K., Nader S., Thomas J. D., Mann D. L., Griffin B. P., Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. Journal of the American College of Cardiology 2000 36 1 208 212 2-s2.0-0033910443 10.1016/S0735-1097(00)00721-X (Pubitemid 30466135)
54. Kastellanos S. S., Toumpoulis I. K., Aggeli C., Zezas S., Chlapoutakis E., Kastellanos S., Stefanadis C. I., Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis. Hellenic Journal of Cardiology 2007 48 1 5 14 2-s2.0-34247574193 (Pubitemid 47621106)
55. Kiechl S., Werner P., Knoflach M., Furtner M., Willeit J., Schett G., The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Review of Cardiovascular Therapy 2006 4 6 801 811 2-s2.0-33845898720 10.1586/14779072.4.6.801 (Pubitemid 46017520)
56. Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A. J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C. R., Lacey D. L., Mak T. W., Boyle W. J., Penninger J. M., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 6717 315 323 2-s2.0-0033611467 10.1038/16852 (Pubitemid 29061638)
57. Nagai M., Kyakumoto S., Sato N., Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochemical and Biophysical Research Communications 2000 269 2 532 536 2-s2.0-0034673525 10.1006/bbrc.2000.2314 (Pubitemid 30440335)
58. Lum L., Wong B. R., Josien R., Becherer J. D., Erdjument-Bromage H., Schlöndorff J., Tempst P., Choi Y., Blobel C. P., Evidence for a role of a tumor necrosis factor- α (TNF- α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. The Journal of Biological Chemistry 1999 274 19 13613 13618 2-s2.0-0033532191 10.1074/jbc.274.19.13613 (Pubitemid 29220502)
59. Schlöndorff J., Lum L., Blobel C. P., Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor α convertase. The Journal of Biological Chemistry 2001 276 18 14665 14674 2-s2.0-0035805620 10.1074/jbc.M010741200
60. Anderson D. M., Maraskovsky E., Billingsley W. L., Dougall W. C., Tometsko M. E., Roux E. R., Teepe M. C., DuBose R. F., Cosman D., Galibert L., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 390 6656 175 179 2-s2.0-0030714605 10.1038/36593 (Pubitemid 27507987)
61. Wong B. R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F. S. III, Frankel W. N., Lee S. Y., Choi Y., TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. The Journal of Biological Chemistry 1997 272 40 25190 25194 2-s2.0-14444272043 10.1074/jbc.272.40.25190 (Pubitemid 27415705)
62. Lacey D. L., Timms E., Tan H.-., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 2-s2.0-0032540319 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
63. Fata J. E., Kong Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R. A., Elliott R., Scully S., Voura E. B., Lacey D. L., Boyle W. J., Khokha R., Penninger J. M., The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000 103 1 41 50 2-s2.0-0034730327
64. Lam J., Nelson C. A., Ross F. P., Teitelbaum S. L., Fremont D. H., Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. Journal of Clinical Investigation 2001 108 7 971 979 2-s2.0-0034784606 10.1172/JCI200113890 (Pubitemid 32946071)
65. Ito S., Wakabayashi K., Ubukata O., Hayashi S., Okada F., Hata T., Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-Å resolution. The Journal of Biological Chemistry 2002 277 8 6631 6636 2-s2.0-0037155157 10.1074/jbc.M106525200 (Pubitemid 34968464)
66. Liu C., Walter T. S., Huang P., Zhang S., Zhu X., Wu Y., Wedderburn L. R., Tang P., Owens R. J., Stuart D. I., Ren J., Gao B., Structural and functional insights of RANKL-RANK interaction and signaling. Journal of Immunology 2010 184 12 6910 6919 2-s2.0-77953623660 10.4049/jimmunol.0904033
67. Kim N., Odgren P. R., Kim D., Marks S. C. Jr., Choi Y., Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10905 10910 2-s2.0-0034718609
68. Odgren P. R., Kim N., MacKay C. A., Mason-Savas A., Choi Y., Marks S. C. Jr., The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue. Connective Tissue Research 2003 44 1 264 271 2-s2.0-12244307844 (Pubitemid 36395455)
69. Lo Iacono N., Pangrazio A., Abinun M., Bredius R., Zecca M., Blair H. C., Vezzoni P., Villa A., Sobacchi C., RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease. Clinical and Developmental Immunology 2013 2013 9 412768 10.1155/2013/412768
70. Douni E., Rinotas V., Makrinou E., Zwerina J., Penninger J. M., Eliopoulos E., Schett G., Kollias G., A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Human Molecular Genetics 2012 21 4 784 798 2-s2.0-84856321770 10.1093/hmg/ddr510
71. Kim D., Mebius R. E., MacMicking J. D., Jung S., Cupedo T., Castellanos Y., Rho J., Wong B. R., Josien R., Kim N., Rennert P. D., Choi Y., Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. Journal of Experimental Medicine 2000 192 10 1467 1478 2-s2.0-0034694090 10.1084/jem.192.10.1467
72. Darnay B. G., Haridas V., Ni J., Moore P. A., Aggarwal B. B., Characterization of the intracellular domain of receptor activator of NF- B (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF- B and c-JUN N-terminal kinase. The Journal of Biological Chemistry 1998 273 32 20551 20555 2-s2.0-0032493737 10.1074/jbc.273.32.20551 (Pubitemid 28377625)
73. Wong B. R., Josien R., Lee S. Y., Vologodskaia M., Steinman R. M., Choi Y., The TRAF family of signal transducers mediates NF- B activation by the TRANCE receptor. The Journal of Biological Chemistry 1998 273 43 28355 28359 2-s2.0-0032561198 10.1074/jbc.273.43.28355 (Pubitemid 28496137)
74. Kim H., Lee D. E., Shin J. N., Lee Y. S., Jeon Y. M., Chung C., Ni J., Kwon B. S., Lee Z. H., Receptor activator of NF- B recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Letters 1999 443 3 297 302 2-s2.0-0033001286 10.1016/S0014-5793(98)01731-1 (Pubitemid 29080814)
75. Nishitoh H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M., Miyazono K., Ichijo H., ASK1 is essential for JNK/SAPK activation by TRAF2. Molecular Cell 1998 2 3 389 395 2-s2.0-0032158987 (Pubitemid 128379279)
76. Hoeflich K. P., Yeh W. C., Yao Z., Mak T. W., Woodgett J. R., Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1). Oncogene 1999 18 42 5814 5820 2-s2.0-0033554554 10.1038/sj.onc.1202975 (Pubitemid 29507435)
77. Wong B. R., Besser D., Kim N., Arron J. R., Vologodskaia M., Hanafusa H., Choi Y., TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell 1999 4 6 1041 1049 2-s2.0-0033393957 (Pubitemid 30054909)
78. Xing L., Venegas A. M., Chen A., Garrett-Beal L., Boyce B. F., Varmus H. E., Schwartzberg P. L., Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes and Development 2001 15 2 241 253 2-s2.0-0035862994 10.1101/gad.840301 (Pubitemid 32107668)
79. Arron J. R., Vologodskaia M., Wong B. R., Naramura M., Kim N., Gu H., Choi Y., A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (TRANCE) and CD40L-mediated Akt activation. The Journal of Biological Chemistry 2001 276 32 30011 30017 2-s2.0-0035839450 10.1074/jbc.M100414200
80. Mizukami J., Takaesu G., Akatsuka H., Sakurai H., Ninomiya-Tsuji J., Matsumoto K., Sakurai N., Receptor activator of NF- B ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Molecular and Cellular Biology 2002 22 4 992 1000 2-s2.0-0036150184 10.1128/MCB.22.4.992-1000.2002 (Pubitemid 34094837)
81. Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., DiPrinzio R., Dodds R. A., James I. E., Rosenberg M., Lee J. C., Young P. R., Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. The Journal of Biological Chemistry 1998 273 23 14363 14367 2-s2.0-7344233085 10.1074/jbc.273.23.14363 (Pubitemid 28319153)
82. Holen I., Croucher P. I., Hamdy F. C., Eaton C. L., Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research 2002 62 6 1619 1623 2-s2.0-0037086077 (Pubitemid 34408480)
83. Brunetti G., Colucci S., Rizzi R., Mori G., Colaianni G., Oranger A., Zallone A., Liso V., Grano M., The role of OPG/TRAIL complex in multiple myeloma. Annals of the New York Academy of Sciences 2006 1068 1 334 340 2-s2.0-33744745283 10.1196/annals.1346.049 (Pubitemid 43824165)
84. Colucci S., Brunetti G., Rizzi R., Zonno A., Mori G., Colaianni G., Del Prete D., Faccio R., Liso A., Capalbo S., Liso V., Zallone A., Grano M., T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004 104 12 3722 3730 2-s2.0-9444231136 10.1182/blood-2004-02-0474 (Pubitemid 39564450)
85. Shipman C. M., Croucher P. I., Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Research 2003 63 5 912 916 2-s2.0-0037374460 (Pubitemid 36278418)
86. Yasuda H., Shima N., Nakagawa N., Mochizuki S., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K., Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 139 3 1329 1337 2-s2.0-0009660825 10.1210/en.139.3.1329 (Pubitemid 28510154)
87. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.-., Trall G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W. J., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 2 309 319 2-s2.0-0031005576 (Pubitemid 27199902)
88. Kwon B. S., Wang S., Udagawa N., Haridas V., Lee Z. H., Kim K. K., Oh K. O., Greene J., Li Y., Su J., Gentz R., Aggarwal B. B., Ni J., TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB Journal 1998 12 10 845 854 2-s2.0-17344381882 (Pubitemid 28294674)
89. Tan K. B., Harrop J., Reddy M., Young P., Terrett J., Emery J., Moore G., Truneh A., Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997 204 1-2 35 46 2-s2.0-0031578808 10.1016/S0378-1119(97)00509-X (Pubitemid 28022168)
90. Yun T. J., Chaudhary P. M., Shu G. L., Frazer J. K., Ewings M. K., Schwartz S. M., Pascual V., Hood L. E., Clark E. A., OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. Journal of Immunology 1998 161 11 6113 6121 2-s2.0-0032400933 (Pubitemid 28535982)
91. Hsu H., Lacey D. L., Dunstan C. R., Solovyev I., Colombero A., Timms E., Tan H. L., Elliott G., Kelley M. J., Sarosi I., Wang L., Xia X. Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M. B., Boyle W. J., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3540 3545 2-s2.0-13044316551 10.1073/pnas.96.7.3540 (Pubitemid 29168945)
92. Dhore C. R., Cleutjens J. P. M., Lutgens E., Cleutjens K. B. J. M., Geusens P. P. M., Kitslaar P. J. E. H. M., Tordoir J. H. M., Spronk H. M. H., Vermeer C., Daemen M. J. A. P., Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 12 1998 2003 2-s2.0-0035571591 (Pubitemid 34219753)
93. Min H., Morony S., Sarosi I., Dunstan C. R., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P. J., Lacey D. L., Boyle W. J., Simonet W. S., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. Journal of Experimental Medicine 2000 192 4 463 474 2-s2.0-0034698926 10.1084/jem.192.4.463 (Pubitemid 30666247)
94. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 9 1260 1268 2-s2.0-0032079445 (Pubitemid 28213402)
95. Panizo S., Cardus A., Encinas M., Parisi E., Valcheva P., López-Ongil S., Coll B., Fernandez E., Valdivielso J. M., RANKL increases vascular smooth muscle cell calcification through a rank-bmp4-dependent pathway. Circulation Research 2009 104 9 1041 1048 2-s2.0-66149095438 10.1161/CIRCRESAHA.108.189001
96. Kaden J. J., Bickelhaupt S., Grobholz R., Haase K. K., Sarikoç A., Kiliç R., Brueckmann M., Lang S., Zahn I., Vahl C., Hagl S., Dempfle C., Borggrefe M., Receptor activator of nuclear factor B ligand and osteoprotegerin regulate aortic valve calcification. Journal of Molecular and Cellular Cardiology 2004 36 1 57 66 2-s2.0-0347004546 10.1016/j.yjmcc.2003.09.015 (Pubitemid 38084791)
97. Steinmetz M., Skowasch D., Wernert N., Welsch U., Preusse C. J., Welz A., Nickenig G., Bauriedel G., Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. The Journal of Heart Valve Disease 2008 17 2 187 193 2-s2.0-50549102361
98. Pohjolainen V., Taskinen P., Soini Y., Rysä J., Ilves M., Juvonen T., Ruskoaho H., Leskinen H., Satta J., Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Human Pathology 2008 39 11 1695 1701 2-s2.0-53849089554 10.1016/j.humpath.2008.04.015
99. Kaden J. J., Dempfle C. E., Kiliç R., Sarikoç A., Hagl S., Lang S., Brueckmann M., Borggrefe M., Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Experimental and Molecular Pathology 2005 78 1 36 40 2-s2.0-16644366212 10.1016/j.yexmp.2004.09.001 (Pubitemid 41373314)
100. Weiss R. M., Lund D. D., Chu Y., Brooks R. M., Zimmerman K. A., El Accaoui R., Davis M. K., Hajj G. P., Zimmerman M. B., Heistad D. D., Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice. PLoS ONE 2013 8 6 e65201 10.1371/journal.pone. 0065201
101. Nagy E., Eriksson P., Yousry M., Caidahl K., Ingelsson E., Hansson G. K., Franco-Cereceda A., Bäck M., Valvular osteoclasts in calcification and aortic valve stenosis severity. International Journal of Cardiology 2013 168 3 2264 2271 10.1016/j.ijcard.2013.01.207
102. Ueland T., Aukrust P., Dahl C. P., Husebye T., Solberg O. G., Tønnessen T., Aakhus S., Gullestad L., Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. Journal of Internal Medicine 2011 270 5 452 460 2-s2.0-80054034731 10.1111/j.1365-2796.2011.02393.x
103. Dahl J. S., Videbæk L., Poulsen M. K., Rudbæk T. R., Christensen N. L., Pellikka P. A., Rasmussen L. M., Møller J. E., Relation of osteoprotegerin in severe aortic valve stenosis to postoperative outcome and left ventricular function. The American Journal of Cardiology 2013 112 9 1433 1438 10.1016/j.amjcard.2013.06.015
104. Motovska Z., Vichova T., Tousek P., Dusek L., Widimsky P., Circulating osteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. International Journal of Cardiology 2012 158 2 300 301 10.1016/j.ijcard.2012.04.115
105. Kimberley F. C., Screaton G. R., Following a TRAIL: update on a ligand and its five receptors. Cell Research 2004 14 5 359 372 2-s2.0-16644372319 10.1038/sj.cr.7290236 (Pubitemid 43231798)
106. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 6 673 682 2-s2.0-13344285339 10.1016/1074-7613(95)90057-8 (Pubitemid 26091143)
107. Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A., Ashkenazi A., Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry 1996 271 22 12687 12690 2-s2.0-17544367410 10.1074/jbc.271.22.12687 (Pubitemid 26175834)
108. Hayakawa Y., Screpanti V., Yagita H., Grandien A., Ljunggren H. G., Smyth M. J., Chambers B. J., NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. Journal of Immunology 2004 172 1 123 129 2-s2.0-0347364696 (Pubitemid 38020463)
109. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005 434 7029 88 93 2-s2.0-14544288632 10.1038/nature03337 (Pubitemid 40349390)
110. Smyth M. J., Takeda K., Hayakawa Y., Peschon J. J., van den Brink M. R. M., Yagita H., Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003 18 1 1 6 2-s2.0-0037240850 10.1016/S1074-7613(02)00502-2 (Pubitemid 36120682)
111. Pan G., O'Rourke K., Chinnaiyan A. M., Gentz R., Ebner R., Ni J., Dixit V. M., The receptor for the cytotoxic ligand TRAIL. Science 1997 276 5309 111 113 2-s2.0-0030996297 10.1126/science.276.5309.111 (Pubitemid 27161256)
112. Pan G., Ni J., Wei Y., Yu G., Gentz R., Dixit V. M., An antagonist decoy
113. Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C. L., Baker K., Wood W. I., Goddard A. D., Godowski P., Ashkenazi A., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997 277 5327 818 821 2-s2.0-0030792712 10.1126/science.277.5327.818 (Pubitemid 27366733)
114. Marsters S. A., Sheridan J. P., Pitti R. M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A. D., Godowski P., Ashkenazi A., A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology 1997 7 12 1003 1006 2-s2.0-13144265771 (Pubitemid 28017080)
115. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X., Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998 94 4 481 490 2-s2.0-0032555716 (Pubitemid 28391864)
116. Li H., Zhu H., Xu C., Yuan J., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998 94 4 491 501 2-s2.0-0032555697 (Pubitemid 28391865)
117. Gross A., Yin X. M., Wang K., Wei M. C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., Korsmeyer S. J., Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-X(L) prevents this release but not tumor necrosis factor-R1/Fas death. The Journal of Biological Chemistry 1999 274 2 1156 1163 2-s2.0-0033534446 10.1074/jbc.274.2. 1156 (Pubitemid 29058093)
118. Danial N. N., Korsmeyer S. J., Cell death: critical control points. Cell 2004 116 2 205 219 2-s2.0-0842281645 10.1016/S0092-8674(04)00046-7 (Pubitemid 38167313)
119. Jin Z., El-Deiry W. S., Overview of cell death signaling pathways. Cancer Biology and Therapy 2005 4 2 139 163 2-s2.0-25144489068 (Pubitemid 41351311)
120. Galluzzi L., Maiuri M. C., Vitale I., Zischka H., Castedo M., Zitvogel L., Kroemer G., Cell death modalities: classification and pathophysiological implications. Cell Death and Differentiation 2007 14 7 1237 1243 2-s2.0-34250753161 10.1038/sj.cdd.4402148 (Pubitemid 46969863)
121. Almasan A., Ashkenazi A., Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine and Growth Factor Reviews 2003 14 3-4 337 348 2-s2.0-0038320035 10.1016/S1359-6101(03)00029-7 (Pubitemid 36693152)
122. Martin-Villalba A., Herr I., Jeremias I., Hahne M., Brandt R., Vogel J., Schenkel J., Herdegen T., Debatin K. M., CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. Journal of Neuroscience 1999 19 10 3809 3817 2-s2.0-0033562658 (Pubitemid 29222257)
123. Jo M. H., Kim T., Seol D. W., Esplen J. E., Dorko K., Billiar T. R., Strom S. C., Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Medicine 2000 6 5 564 567 2-s2.0-0034022160 10.1038/75045 (Pubitemid 30305907)
124. Roux S., Lambert-Comeau P., Saint-Pierre C., Lépine M., Sawan B., Parent J. L., Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochemical and Biophysical Research Communications 2005 333 1 42 50 2-s2.0-20444458264 10.1016/j.bbrc.2005.05.092 (Pubitemid 40813444)
125. Colucci S., Brunetti G., Cantatore F. P., Oranger A., Mori G., Pignataro P., Tamma R., Grassi F. R., Zallone A., Grano M., The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 2007 12 9 1623 1632 2-s2.0-34547104357 10.1007/s10495-007-0095-3 (Pubitemid 47106894)
126. Brunetti G., Oranger A., Mori G., Tamma R., Di Benedetto A., Pignataro P., Grassi F. R., Zallone A., Grano M., Colucci S., TRAIL is involved in human osteoclast apoptosis. Annals of the New York Academy of Sciences 2007 1116 316 322 2-s2.0-37249038974 10.1196/annals.1402.011 (Pubitemid 350274317)
127. Brunetti G., Oranger A., Carbone C., Mori G., Sardone F. R., Mori C., Celi M., Faienza M. F., Tarantino U., Zallone A., Grano M., Colucci S., Osteoblasts display different responsiveness to TRAIL-induced apoptosis during their differentiation process. Cell Biochemistry and Biophysics 2013 10.1007/s12013-013-9616-6
128. Mori G., Brunetti G., Collucci S., Oranger A., Ciccolella F., Sardone F., Pignataro P., Mori C., Karapanou V., Ballini A., Mastrangelo F., Tetè S., Grassi F. R., Grano M., Osteoblast apoptosis in periodontal disease: role of TNF-related apoptosis-inducing ligand. International Journal of Immunopathology and Pharmacology 2009 22 1 95 103 2-s2.0-62649131718
129. Mori G., Brunetti G., Colucci S., Ciccolella F., Coricciati M., Pignataro P., Oranger A., Ballini A., Farronato D., Mastrangelo F., Tetè S., Grassi F. R., Grano M., Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL. Journal of Biological Regulators and Homeostatic Agents 2007 21 3-4 105 114 2-s2.0-42149149379 (Pubitemid 351524044)
130. Sato K., Niessner A., Kopecky S. L., Frye R. L., Goronzy J. J., Weyand C. M., TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. Journal of Experimental Medicine 2006 203 1 239 250 2-s2.0-31344460566 10.1084/jem.20051062 (Pubitemid 43139661)
131. Proudfoot D., Skepper J. N., Hegyi L., Bennett M. R., Shanahan C. M., Weissberg P. L., Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circulation Research 2000 87 11 1055 1062 2-s2.0-0034711505
132. Clark-Greuel J. N., Connolly J. M., Sorichillo E., Narula N. R., Rapoport H. S., Mohler E. R. III, Gorman J. H. III, Gorman R. C., Levy R. J., Transforming growth factor- β 1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Annals of Thoracic Surgery 2007 83 3 946 953 2-s2.0-33847293734 10.1016/j.athoracsur.2006.10.026 (Pubitemid 46328821)
133. Gu X., Masters K. S., Role of the MAPK/ERK pathway in valvular interstitial cell calcification. The American Journal of Physiology-Heart and Circulatory Physiology 2009 296 6 H1748 H1757 2-s2.0-66949118241 10.1152/ajpheart.00099.2009
134. Schoppet M., Al-Fakhri N., Franke F. E., Katz N., Barth P. J., Maisch B., Preissner K. T., Hofbauer L. C., Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor- B ligand in Mönckeberg's sclerosis and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2004 89 8 4104 4112 2-s2.0-4043158681 10.1210/jc.2003-031432 (Pubitemid 39071519)
135. Moen M. D., Keam S. J., Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs and Aging 2011 28 1 63 82 2-s2.0-78650651667 10.2165/11203300-000000000-00000
136. Corrado A., Neve A., Maruotti N., Cantatore F. P., Bone effects of biologic drugs in rheumatoid arthritis. Clinical and Developmental Immunology 2013 2013 7 945945 10.1155/2013/945945
137. Hjortnaes J., Butcher J., Figueiredo J. L., Riccio M., Kohler R. H., Kozloff K. M., Weissleder R., Aikawa E., Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. European Heart Journal 2010 31 16 1975 1984 2-s2.0-77955943689 10.1093/eurheartj/ehq237